Mineralys Therapeutics, Inc Common Stock
Price & Volume
Stats
See more52W Range | $8.24-$47.65 |
Market Cap | $2.9B |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.92 |
News
See moreYahoo Finance • 2 days ago
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Yahoo Finance • 13 days ago
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
Yahoo Finance • 29 days ago
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance • last month
Mineralys outlines NDA submission timeline and advances lorundrostat trials amid expanded clinical focus
About
CEO | Mr. Jon Congleton |
CFO | Mr. Adam Scott Levy |
Address | 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 51 |
